ATXI · XBRL financial data
Avenue Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ATXI's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 0 | 1,404 |
| Research and development | 2,866 | 1,254 | 2,698 | 6,131 | 6,645 | 1,037 |
| General and administrative | 2,347 | 2,484 | 5,345 | 4,179 | 4,638 | 3,653 |
| Total operating expenses | — | — | — | — | 11,283 | 4,487 |
| Operating income (loss) | (5,213) | (3,738) | (8,043) | (14,540) | (11,283) | (3,083) |
| Interest income | 62 | 7 | 20 | 126 | 176 | 121 |
| Income tax expense (benefit) | — | — | 0 | 0 | 0 | 2 |
| Net income (loss) | (5,151) | (3,731) | (3,552) | — | (11,652) | (2,909) |
| Earnings per share, basic‡ USD per share | (348.75) | (247.50) | (122.25) | (73.50) | (15.79) | (0.93) |
| Earnings per share, diluted‡ USD per share | (348.75) | (247.50) | — | — | — | — |
| Weighted average shares, basic‡ thousands of shares | 15 | 15 | 29 | 141 | 1,295 | 3,131 |
| Weighted average shares, diluted‡ thousands of shares | 15 | 15 | 29 | — | — | — |
- ‡ Per-share figures and share counts are adjusted for the 1-for-15 stock split (September 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-75 stock split (December 2024); filings made before it reported them unadjusted.
- † Share count changed about 4x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (ATXI's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3,132 | 3,763 | 6,708 | 1,783 | 2,594 | 2,855 |
| Prepaid and other current assets | 113 | 107 | 137 | 67 | 78 | 76 |
| Total current assets | 3,245 | 3,960 | — | — | — | — |
| Total assets | 3,245 | 3,960 | 6,845 | 1,850 | 2,672 | 2,931 |
| Accounts payable | 143 | 304 | 129 | 78 | 155 | — |
| Total current liabilities | 886 | 509 | 3,579 | 1,196 | 816 | 1,099 |
| Total liabilities | 886 | 509 | 3,579 | 1,196 | 816 | 1,099 |
| Accumulated deficit | (73,268) | (76,999) | (80,551) | (90,928) | (102,580) | (105,489) |
| Total stockholders' equity | 2,359 | 3,451 | 3,905 | 1,582 | 2,797 | 1,832 |
| Total liabilities and equity | 3,245 | 3,960 | 6,845 | 1,850 | 2,672 | 2,931 |
| Common shares outstanding (cover page)‡ thousands of shares | 15 | 19 | 79 | 590 | 3,150 | 3,295 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-15 stock split (September 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-75 stock split (December 2024); filings made before it reported them unadjusted.
- † Share count changed about 4x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (ATXI's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (5,151) | (3,731) | (3,552) | — | (11,652) | (2,909) |
| Stock-based compensation | 710 | 442 | 649 | 906 | 1,236 | 665 |
| Net cash from operating activities | (4,613) | (3,750) | (7,596) | (9,451) | (9,026) | (1,833) |
| Net cash from investing activities | (1,000) | — | 0 | (3,000) | 0 | — |
| Proceeds from issuing common stock | 0 | 5,044 | — | 0 | 1,623 | 2,094 |
| Share repurchases | — | — | 1,104 | 0 | — | — |
| Net cash from financing activities | 0 | 4,381 | 10,541 | 7,526 | 9,837 | 2,094 |
- † Share count changed about 4x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Avenue Therapeutics | 1,942 | 0 | (475)* | 3.3M | 4.1 quarters | 10-QJun 30, 2026 |
| Emmaus Life Sciences | 2,808 | 6,318 | 1,693* | 70.2M | — | 10-QJun 30, 2026 |
| International Stem Cell | 1,089 | 2,675 | 167* | 8.0M | — | 10-QJun 30, 2026 |
| Nutra Pharma | not reported | 34 | (251)* | 7.2B | 0.1 quarters | 10-QJun 30, 2026 |
| Mosaic ImmunoEngineering | 0 | not reported | (0)* | 7.2M | 0.6 quarters | 10-QJun 30, 2026 |
| China Foods Holdings | 16 | 0 | (94)* | 20.3M | 0.2 quarters | 10-QJun 30, 2026 |
| Hepion Pharmaceuticals | 1,629 | not reported | (1,394)* | 90.2M | 1.2 quarters | 10-QJun 30, 2026 |
| NovAccess Global | 21 | 0* | (55)* | 61.7M | 0.4 quarters | 10-KSep 30, 2024 |
| Eloxx Pharmaceuticals | 61,960 | not reported | (4,789)* | 4.0M | 12.9 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.